Jefferies Financial Group Inc. Acquires 3,784 Shares of AbbVie Inc. $ABBV

Jefferies Financial Group Inc. raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.8% in the fourth quarter, HoldingsChannel reports. The firm owned 103,457 shares of the company’s stock after buying an additional 3,784 shares during the quarter. Jefferies Financial Group Inc.’s holdings in AbbVie were worth $23,639,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC bought a new position in AbbVie during the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the 3rd quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID raised its position in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC raised its position in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $216.02 on Friday. AbbVie Inc. has a 52-week low of $181.71 and a 52-week high of $244.81. The firm has a market capitalization of $381.65 billion, a P/E ratio of 106.41, a P/E/G ratio of 0.74 and a beta of 0.32. The stock has a 50 day moving average price of $208.72 and a 200-day moving average price of $219.68.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the prior year, the company earned $2.46 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. On average, equities analysts forecast that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Citigroup decreased their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Finally, Guggenheim reissued a “buy” rating and issued a $249.00 target price on shares of AbbVie in a research report on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $253.43.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
• Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
• Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
• Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.